カテゴリー： 世界, 医療/バイオ, QYResearch

超短時間作用型ベンゾジアゼピンの世界市場インサイト・予測（～2028年）

【英語タイトル】Global Ultra Short Acting Benzodiazepines Market Insights, Forecast to 2028

QYResearchが出版した調査資料（QY22JLX10511）・商品コード：QY22JLX10511
・発行会社（調査会社）：QYResearch
・発行日：2022年7月（※2025年版があります。お問い合わせください。）
・ページ数：109
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥735,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,102,500見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,470,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

COVID-19のパンデミックにより、超短時間作用型ベンゾジアゼピンのグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に超短時間作用型ベンゾジアゼピンの世界市場のxxx％を占める「クロラゼプ酸」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
超短時間作用型ベンゾジアゼピンの中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの超短時間作用型ベンゾジアゼピン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

超短時間作用型ベンゾジアゼピンのグローバル主要企業には、Roche、Pfizer、Bausch Health、Mylan、Novartis、Teva Pharmaceutical、Lundbeck、Amneal Pharmaceuticals、Sun Pharmaceutical、Apotex、Aurobindo Pharmaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

超短時間作用型ベンゾジアゼピン市場は、種類と用途によって区分されます。世界の超短時間作用型ベンゾジアゼピン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
クロラゼプ酸、ベルセド、ハルシオン

【用途別セグメント】
病院薬局、小売薬局、オンライン薬局

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 超短時間作用型ベンゾジアゼピン製品概要
- 種類別市場（クロラゼプ酸、ベルセド、ハルシオン）
- 用途別市場（病院薬局、小売薬局、オンライン薬局）
- 調査の目的
・エグゼクティブサマリー
- 世界の超短時間作用型ベンゾジアゼピン販売量予測2017-2028
- 世界の超短時間作用型ベンゾジアゼピン売上予測2017-2028
- 超短時間作用型ベンゾジアゼピンの地域別販売量
- 超短時間作用型ベンゾジアゼピンの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別超短時間作用型ベンゾジアゼピン販売量
- 主要メーカー別超短時間作用型ベンゾジアゼピン売上
- 主要メーカー別超短時間作用型ベンゾジアゼピン価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（クロラゼプ酸、ベルセド、ハルシオン）
- 超短時間作用型ベンゾジアゼピンの種類別販売量
- 超短時間作用型ベンゾジアゼピンの種類別売上
- 超短時間作用型ベンゾジアゼピンの種類別価格
・用途別市場規模（病院薬局、小売薬局、オンライン薬局）
- 超短時間作用型ベンゾジアゼピンの用途別販売量
- 超短時間作用型ベンゾジアゼピンの用途別売上
- 超短時間作用型ベンゾジアゼピンの用途別価格
・北米市場
- 北米の超短時間作用型ベンゾジアゼピン市場規模（種類別、用途別）
- 主要国別の超短時間作用型ベンゾジアゼピン市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの超短時間作用型ベンゾジアゼピン市場規模（種類別、用途別）
- 主要国別の超短時間作用型ベンゾジアゼピン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の超短時間作用型ベンゾジアゼピン市場規模（種類別、用途別）
- 主要国別の超短時間作用型ベンゾジアゼピン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の超短時間作用型ベンゾジアゼピン市場規模（種類別、用途別）
- 主要国別の超短時間作用型ベンゾジアゼピン市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの超短時間作用型ベンゾジアゼピン市場規模（種類別、用途別）
- 主要国別の超短時間作用型ベンゾジアゼピン市場規模（トルコ、サウジアラビア）
・企業情報
Roche、Pfizer、Bausch Health、Mylan、Novartis、Teva Pharmaceutical、Lundbeck、Amneal Pharmaceuticals、Sun Pharmaceutical、Apotex、Aurobindo Pharma
・産業チェーン及び販売チャネル分析
- 超短時間作用型ベンゾジアゼピンの産業チェーン分析
- 超短時間作用型ベンゾジアゼピンの原材料
- 超短時間作用型ベンゾジアゼピンの生産プロセス
- 超短時間作用型ベンゾジアゼピンの販売及びマーケティング
- 超短時間作用型ベンゾジアゼピンの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 超短時間作用型ベンゾジアゼピンの産業動向
- 超短時間作用型ベンゾジアゼピンのマーケットドライバー
- 超短時間作用型ベンゾジアゼピンの課題
- 超短時間作用型ベンゾジアゼピンの阻害要因
・主な調査結果

Market Analysis and Insights: Global Ultra Short Acting Benzodiazepines Market
Due to the COVID-19 pandemic, the global Ultra Short Acting Benzodiazepines market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Clorazepate accounting for % of the Ultra Short Acting Benzodiazepines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Ultra Short Acting Benzodiazepines market size is valued at US$ million in 2021, while the US and Europe Ultra Short Acting Benzodiazepines are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Ultra Short Acting Benzodiazepines landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Ultra Short Acting Benzodiazepines include Roche, Pfizer, Bausch Health, Mylan, Novartis, Teva Pharmaceutical, Lundbeck, Amneal Pharmaceuticals and Sun Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Ultra Short Acting Benzodiazepines Scope and Segment
Ultra Short Acting Benzodiazepines market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Ultra Short Acting Benzodiazepines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Clorazepate
Versed
Halcion
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Company
Roche
Pfizer
Bausch Health
Mylan
Novartis
Teva Pharmaceutical
Lundbeck
Amneal Pharmaceuticals
Sun Pharmaceutical
Apotex
Aurobindo Pharma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Ultra Short Acting Benzodiazepines Product Introduction
1.2 Market by Type
1.2.1 Global Ultra Short Acting Benzodiazepines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Clorazepate
1.2.3 Versed
1.2.4 Halcion
1.3 Market by Application
1.3.1 Global Ultra Short Acting Benzodiazepines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Ultra Short Acting Benzodiazepines Sales Estimates and Forecasts 2017-2028
2.2 Global Ultra Short Acting Benzodiazepines Revenue Estimates and Forecasts 2017-2028
2.3 Global Ultra Short Acting Benzodiazepines Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Ultra Short Acting Benzodiazepines Sales by Region
2.4.1 Global Ultra Short Acting Benzodiazepines Sales by Region (2017-2022)
2.4.2 Global Sales Ultra Short Acting Benzodiazepines by Region (2023-2028)
2.5 Global Ultra Short Acting Benzodiazepines Revenue by Region
2.5.1 Global Ultra Short Acting Benzodiazepines Revenue by Region (2017-2022)
2.5.2 Global Ultra Short Acting Benzodiazepines Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Ultra Short Acting Benzodiazepines Sales by Manufacturers
3.1.1 Global Top Ultra Short Acting Benzodiazepines Manufacturers by Sales (2017-2022)
3.1.2 Global Ultra Short Acting Benzodiazepines Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Ultra Short Acting Benzodiazepines in 2021
3.2 Global Ultra Short Acting Benzodiazepines Revenue by Manufacturers
3.2.1 Global Ultra Short Acting Benzodiazepines Revenue by Manufacturers (2017-2022)
3.2.2 Global Ultra Short Acting Benzodiazepines Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Ultra Short Acting Benzodiazepines Revenue in 2021
3.3 Global Ultra Short Acting Benzodiazepines Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Ultra Short Acting Benzodiazepines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Ultra Short Acting Benzodiazepines Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Ultra Short Acting Benzodiazepines Sales by Type
4.1.1 Global Ultra Short Acting Benzodiazepines Historical Sales by Type (2017-2022)
4.1.2 Global Ultra Short Acting Benzodiazepines Forecasted Sales by Type (2023-2028)
4.1.3 Global Ultra Short Acting Benzodiazepines Sales Market Share by Type (2017-2028)
4.2 Global Ultra Short Acting Benzodiazepines Revenue by Type
4.2.1 Global Ultra Short Acting Benzodiazepines Historical Revenue by Type (2017-2022)
4.2.2 Global Ultra Short Acting Benzodiazepines Forecasted Revenue by Type (2023-2028)
4.2.3 Global Ultra Short Acting Benzodiazepines Revenue Market Share by Type (2017-2028)
4.3 Global Ultra Short Acting Benzodiazepines Price by Type
4.3.1 Global Ultra Short Acting Benzodiazepines Price by Type (2017-2022)
4.3.2 Global Ultra Short Acting Benzodiazepines Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Ultra Short Acting Benzodiazepines Sales by Application
5.1.1 Global Ultra Short Acting Benzodiazepines Historical Sales by Application (2017-2022)
5.1.2 Global Ultra Short Acting Benzodiazepines Forecasted Sales by Application (2023-2028)
5.1.3 Global Ultra Short Acting Benzodiazepines Sales Market Share by Application (2017-2028)
5.2 Global Ultra Short Acting Benzodiazepines Revenue by Application
5.2.1 Global Ultra Short Acting Benzodiazepines Historical Revenue by Application (2017-2022)
5.2.2 Global Ultra Short Acting Benzodiazepines Forecasted Revenue by Application (2023-2028)
5.2.3 Global Ultra Short Acting Benzodiazepines Revenue Market Share by Application (2017-2028)
5.3 Global Ultra Short Acting Benzodiazepines Price by Application
5.3.1 Global Ultra Short Acting Benzodiazepines Price by Application (2017-2022)
5.3.2 Global Ultra Short Acting Benzodiazepines Price Forecast by Application (2023-2028)
6 North America
6.1 North America Ultra Short Acting Benzodiazepines Market Size by Type
6.1.1 North America Ultra Short Acting Benzodiazepines Sales by Type (2017-2028)
6.1.2 North America Ultra Short Acting Benzodiazepines Revenue by Type (2017-2028)
6.2 North America Ultra Short Acting Benzodiazepines Market Size by Application
6.2.1 North America Ultra Short Acting Benzodiazepines Sales by Application (2017-2028)
6.2.2 North America Ultra Short Acting Benzodiazepines Revenue by Application (2017-2028)
6.3 North America Ultra Short Acting Benzodiazepines Market Size by Country
6.3.1 North America Ultra Short Acting Benzodiazepines Sales by Country (2017-2028)
6.3.2 North America Ultra Short Acting Benzodiazepines Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Ultra Short Acting Benzodiazepines Market Size by Type
7.1.1 Europe Ultra Short Acting Benzodiazepines Sales by Type (2017-2028)
7.1.2 Europe Ultra Short Acting Benzodiazepines Revenue by Type (2017-2028)
7.2 Europe Ultra Short Acting Benzodiazepines Market Size by Application
7.2.1 Europe Ultra Short Acting Benzodiazepines Sales by Application (2017-2028)
7.2.2 Europe Ultra Short Acting Benzodiazepines Revenue by Application (2017-2028)
7.3 Europe Ultra Short Acting Benzodiazepines Market Size by Country
7.3.1 Europe Ultra Short Acting Benzodiazepines Sales by Country (2017-2028)
7.3.2 Europe Ultra Short Acting Benzodiazepines Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Ultra Short Acting Benzodiazepines Market Size by Type
8.1.1 Asia Pacific Ultra Short Acting Benzodiazepines Sales by Type (2017-2028)
8.1.2 Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Type (2017-2028)
8.2 Asia Pacific Ultra Short Acting Benzodiazepines Market Size by Application
8.2.1 Asia Pacific Ultra Short Acting Benzodiazepines Sales by Application (2017-2028)
8.2.2 Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Application (2017-2028)
8.3 Asia Pacific Ultra Short Acting Benzodiazepines Market Size by Region
8.3.1 Asia Pacific Ultra Short Acting Benzodiazepines Sales by Region (2017-2028)
8.3.2 Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Ultra Short Acting Benzodiazepines Market Size by Type
9.1.1 Latin America Ultra Short Acting Benzodiazepines Sales by Type (2017-2028)
9.1.2 Latin America Ultra Short Acting Benzodiazepines Revenue by Type (2017-2028)
9.2 Latin America Ultra Short Acting Benzodiazepines Market Size by Application
9.2.1 Latin America Ultra Short Acting Benzodiazepines Sales by Application (2017-2028)
9.2.2 Latin America Ultra Short Acting Benzodiazepines Revenue by Application (2017-2028)
9.3 Latin America Ultra Short Acting Benzodiazepines Market Size by Country
9.3.1 Latin America Ultra Short Acting Benzodiazepines Sales by Country (2017-2028)
9.3.2 Latin America Ultra Short Acting Benzodiazepines Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Ultra Short Acting Benzodiazepines Market Size by Type
10.1.1 Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Type (2017-2028)
10.1.2 Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Type (2017-2028)
10.2 Middle East and Africa Ultra Short Acting Benzodiazepines Market Size by Application
10.2.1 Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Application (2017-2028)
10.2.2 Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Application (2017-2028)
10.3 Middle East and Africa Ultra Short Acting Benzodiazepines Market Size by Country
10.3.1 Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Country (2017-2028)
10.3.2 Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Overview
11.1.3 Roche Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Roche Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Roche Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Pfizer Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer Recent Developments
11.3 Bausch Health
11.3.1 Bausch Health Corporation Information
11.3.2 Bausch Health Overview
11.3.3 Bausch Health Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Bausch Health Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bausch Health Recent Developments
11.4 Mylan
11.4.1 Mylan Corporation Information
11.4.2 Mylan Overview
11.4.3 Mylan Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Mylan Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Mylan Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Overview
11.5.3 Novartis Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Novartis Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Recent Developments
11.6 Teva Pharmaceutical
11.6.1 Teva Pharmaceutical Corporation Information
11.6.2 Teva Pharmaceutical Overview
11.6.3 Teva Pharmaceutical Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Teva Pharmaceutical Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Teva Pharmaceutical Recent Developments
11.7 Lundbeck
11.7.1 Lundbeck Corporation Information
11.7.2 Lundbeck Overview
11.7.3 Lundbeck Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Lundbeck Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Lundbeck Recent Developments
11.8 Amneal Pharmaceuticals
11.8.1 Amneal Pharmaceuticals Corporation Information
11.8.2 Amneal Pharmaceuticals Overview
11.8.3 Amneal Pharmaceuticals Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Amneal Pharmaceuticals Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Amneal Pharmaceuticals Recent Developments
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Corporation Information
11.9.2 Sun Pharmaceutical Overview
11.9.3 Sun Pharmaceutical Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Sun Pharmaceutical Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sun Pharmaceutical Recent Developments
11.10 Apotex
11.10.1 Apotex Corporation Information
11.10.2 Apotex Overview
11.10.3 Apotex Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Apotex Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Apotex Recent Developments
11.11 Aurobindo Pharma
11.11.1 Aurobindo Pharma Corporation Information
11.11.2 Aurobindo Pharma Overview
11.11.3 Aurobindo Pharma Ultra Short Acting Benzodiazepines Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Aurobindo Pharma Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Aurobindo Pharma Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Ultra Short Acting Benzodiazepines Industry Chain Analysis
12.2 Ultra Short Acting Benzodiazepines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Ultra Short Acting Benzodiazepines Production Mode & Process
12.4 Ultra Short Acting Benzodiazepines Sales and Marketing
12.4.1 Ultra Short Acting Benzodiazepines Sales Channels
12.4.2 Ultra Short Acting Benzodiazepines Distributors
12.5 Ultra Short Acting Benzodiazepines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Ultra Short Acting Benzodiazepines Industry Trends
13.2 Ultra Short Acting Benzodiazepines Market Drivers
13.3 Ultra Short Acting Benzodiazepines Market Challenges
13.4 Ultra Short Acting Benzodiazepines Market Restraints
14 Key Findings in The Global Ultra Short Acting Benzodiazepines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Ultra Short Acting Benzodiazepines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Clorazepate
Table 3. Major Manufacturers of Versed
Table 4. Major Manufacturers of Halcion
Table 5. Global Ultra Short Acting Benzodiazepines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Ultra Short Acting Benzodiazepines Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Ultra Short Acting Benzodiazepines Sales by Region (2017-2022) & (K Units)
Table 8. Global Ultra Short Acting Benzodiazepines Sales Market Share by Region (2017-2022)
Table 9. Global Ultra Short Acting Benzodiazepines Sales by Region (2023-2028) & (K Units)
Table 10. Global Ultra Short Acting Benzodiazepines Sales Market Share by Region (2023-2028)
Table 11. Global Ultra Short Acting Benzodiazepines Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Ultra Short Acting Benzodiazepines Revenue Market Share by Region (2017-2022)
Table 13. Global Ultra Short Acting Benzodiazepines Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Ultra Short Acting Benzodiazepines Revenue Market Share by Region (2023-2028)
Table 15. Global Ultra Short Acting Benzodiazepines Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Ultra Short Acting Benzodiazepines Sales Share by Manufacturers (2017-2022)
Table 17. Global Ultra Short Acting Benzodiazepines Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Ultra Short Acting Benzodiazepines Revenue Share by Manufacturers (2017-2022)
Table 19. Ultra Short Acting Benzodiazepines Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Ultra Short Acting Benzodiazepines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Ultra Short Acting Benzodiazepines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ultra Short Acting Benzodiazepines as of 2021)
Table 22. Ultra Short Acting Benzodiazepines Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Ultra Short Acting Benzodiazepines Product Offered
Table 24. Date of Manufacturers Enter into Ultra Short Acting Benzodiazepines Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Ultra Short Acting Benzodiazepines Sales by Type (2017-2022) & (K Units)
Table 27. Global Ultra Short Acting Benzodiazepines Sales by Type (2023-2028) & (K Units)
Table 28. Global Ultra Short Acting Benzodiazepines Sales Share by Type (2017-2022)
Table 29. Global Ultra Short Acting Benzodiazepines Sales Share by Type (2023-2028)
Table 30. Global Ultra Short Acting Benzodiazepines Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Ultra Short Acting Benzodiazepines Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Ultra Short Acting Benzodiazepines Revenue Share by Type (2017-2022)
Table 33. Global Ultra Short Acting Benzodiazepines Revenue Share by Type (2023-2028)
Table 34. Ultra Short Acting Benzodiazepines Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Ultra Short Acting Benzodiazepines Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Ultra Short Acting Benzodiazepines Sales by Application (2017-2022) & (K Units)
Table 37. Global Ultra Short Acting Benzodiazepines Sales by Application (2023-2028) & (K Units)
Table 38. Global Ultra Short Acting Benzodiazepines Sales Share by Application (2017-2022)
Table 39. Global Ultra Short Acting Benzodiazepines Sales Share by Application (2023-2028)
Table 40. Global Ultra Short Acting Benzodiazepines Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Ultra Short Acting Benzodiazepines Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Ultra Short Acting Benzodiazepines Revenue Share by Application (2017-2022)
Table 43. Global Ultra Short Acting Benzodiazepines Revenue Share by Application (2023-2028)
Table 44. Ultra Short Acting Benzodiazepines Price by Application (2017-2022) & (US$/Unit)
Table 45. Global Ultra Short Acting Benzodiazepines Price Forecast by Application (2023-2028) & (US$/Unit)
Table 46. North America Ultra Short Acting Benzodiazepines Sales by Type (2017-2022) & (K Units)
Table 47. North America Ultra Short Acting Benzodiazepines Sales by Type (2023-2028) & (K Units)
Table 48. North America Ultra Short Acting Benzodiazepines Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Ultra Short Acting Benzodiazepines Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Ultra Short Acting Benzodiazepines Sales by Application (2017-2022) & (K Units)
Table 51. North America Ultra Short Acting Benzodiazepines Sales by Application (2023-2028) & (K Units)
Table 52. North America Ultra Short Acting Benzodiazepines Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Ultra Short Acting Benzodiazepines Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Ultra Short Acting Benzodiazepines Sales by Country (2017-2022) & (K Units)
Table 55. North America Ultra Short Acting Benzodiazepines Sales by Country (2023-2028) & (K Units)
Table 56. North America Ultra Short Acting Benzodiazepines Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Ultra Short Acting Benzodiazepines Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Ultra Short Acting Benzodiazepines Sales by Type (2017-2022) & (K Units)
Table 59. Europe Ultra Short Acting Benzodiazepines Sales by Type (2023-2028) & (K Units)
Table 60. Europe Ultra Short Acting Benzodiazepines Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Ultra Short Acting Benzodiazepines Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Ultra Short Acting Benzodiazepines Sales by Application (2017-2022) & (K Units)
Table 63. Europe Ultra Short Acting Benzodiazepines Sales by Application (2023-2028) & (K Units)
Table 64. Europe Ultra Short Acting Benzodiazepines Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Ultra Short Acting Benzodiazepines Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Ultra Short Acting Benzodiazepines Sales by Country (2017-2022) & (K Units)
Table 67. Europe Ultra Short Acting Benzodiazepines Sales by Country (2023-2028) & (K Units)
Table 68. Europe Ultra Short Acting Benzodiazepines Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Ultra Short Acting Benzodiazepines Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Ultra Short Acting Benzodiazepines Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Ultra Short Acting Benzodiazepines Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Ultra Short Acting Benzodiazepines Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific Ultra Short Acting Benzodiazepines Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Ultra Short Acting Benzodiazepines Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Ultra Short Acting Benzodiazepines Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Ultra Short Acting Benzodiazepines Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Ultra Short Acting Benzodiazepines Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Ultra Short Acting Benzodiazepines Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Ultra Short Acting Benzodiazepines Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Ultra Short Acting Benzodiazepines Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Ultra Short Acting Benzodiazepines Sales by Application (2017-2022) & (K Units)
Table 87. Latin America Ultra Short Acting Benzodiazepines Sales by Application (2023-2028) & (K Units)
Table 88. Latin America Ultra Short Acting Benzodiazepines Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Ultra Short Acting Benzodiazepines Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Ultra Short Acting Benzodiazepines Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Ultra Short Acting Benzodiazepines Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Ultra Short Acting Benzodiazepines Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Ultra Short Acting Benzodiazepines Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Ultra Short Acting Benzodiazepines Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue by Country (2023-2028) & (US$ Million)
Table 106. Roche Corporation Information
Table 107. Roche Description and Major Businesses
Table 108. Roche Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. Roche Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Roche Recent Developments
Table 111. Pfizer Corporation Information
Table 112. Pfizer Description and Major Businesses
Table 113. Pfizer Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Pfizer Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Pfizer Recent Developments
Table 116. Bausch Health Corporation Information
Table 117. Bausch Health Description and Major Businesses
Table 118. Bausch Health Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Bausch Health Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Bausch Health Recent Developments
Table 121. Mylan Corporation Information
Table 122. Mylan Description and Major Businesses
Table 123. Mylan Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Mylan Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Mylan Recent Developments
Table 126. Novartis Corporation Information
Table 127. Novartis Description and Major Businesses
Table 128. Novartis Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. Novartis Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Novartis Recent Developments
Table 131. Teva Pharmaceutical Corporation Information
Table 132. Teva Pharmaceutical Description and Major Businesses
Table 133. Teva Pharmaceutical Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. Teva Pharmaceutical Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Teva Pharmaceutical Recent Developments
Table 136. Lundbeck Corporation Information
Table 137. Lundbeck Description and Major Businesses
Table 138. Lundbeck Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. Lundbeck Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Lundbeck Recent Developments
Table 141. Amneal Pharmaceuticals Corporation Information
Table 142. Amneal Pharmaceuticals Description and Major Businesses
Table 143. Amneal Pharmaceuticals Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. Amneal Pharmaceuticals Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Amneal Pharmaceuticals Recent Developments
Table 146. Sun Pharmaceutical Corporation Information
Table 147. Sun Pharmaceutical Description and Major Businesses
Table 148. Sun Pharmaceutical Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 149. Sun Pharmaceutical Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Sun Pharmaceutical Recent Developments
Table 151. Apotex Corporation Information
Table 152. Apotex Description and Major Businesses
Table 153. Apotex Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 154. Apotex Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Apotex Recent Developments
Table 156. Aurobindo Pharma Corporation Information
Table 157. Aurobindo Pharma Description and Major Businesses
Table 158. Aurobindo Pharma Ultra Short Acting Benzodiazepines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 159. Aurobindo Pharma Ultra Short Acting Benzodiazepines Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Aurobindo Pharma Recent Developments
Table 161. Key Raw Materials Lists
Table 162. Raw Materials Key Suppliers Lists
Table 163. Ultra Short Acting Benzodiazepines Distributors List
Table 164. Ultra Short Acting Benzodiazepines Customers List
Table 165. Ultra Short Acting Benzodiazepines Market Trends
Table 166. Ultra Short Acting Benzodiazepines Market Drivers
Table 167. Ultra Short Acting Benzodiazepines Market Challenges
Table 168. Ultra Short Acting Benzodiazepines Market Restraints
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Ultra Short Acting Benzodiazepines Product Picture
Figure 3. Global Ultra Short Acting Benzodiazepines Market Share by Type in 2021 & 2028
Figure 3. Clorazepate Product Picture
Figure 4. Versed Product Picture
Figure 5. Halcion Product Picture
Figure 6. Global Ultra Short Acting Benzodiazepines Market Share by Application in 2021 & 2028
Figure 7. Hospital Pharmacies
Figure 8. Retail Pharmacies
Figure 9. Online Pharmacies
Figure 10. Ultra Short Acting Benzodiazepines Report Years Considered
Figure 11. Global Ultra Short Acting Benzodiazepines Sales 2017-2028 (K Units)
Figure 12. Global Ultra Short Acting Benzodiazepines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Ultra Short Acting Benzodiazepines Revenue 2017-2028 (US$ Million)
Figure 14. Global Ultra Short Acting Benzodiazepines Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Ultra Short Acting Benzodiazepines Sales Market Share by Region (2017-2022)
Figure 16. Global Ultra Short Acting Benzodiazepines Sales Market Share by Region (2023-2028)
Figure 17. North America Ultra Short Acting Benzodiazepines Sales YoY (2017-2028) & (K Units)
Figure 18. North America Ultra Short Acting Benzodiazepines Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Ultra Short Acting Benzodiazepines Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Ultra Short Acting Benzodiazepines Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Ultra Short Acting Benzodiazepines Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Ultra Short Acting Benzodiazepines Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Ultra Short Acting Benzodiazepines Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Ultra Short Acting Benzodiazepines Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Ultra Short Acting Benzodiazepines Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Ultra Short Acting Benzodiazepines Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Ultra Short Acting Benzodiazepines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Ultra Short Acting Benzodiazepines in the World: Market Share by Ultra Short Acting Benzodiazepines Revenue in 2021
Figure 29. Global Ultra Short Acting Benzodiazepines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Ultra Short Acting Benzodiazepines Sales Market Share by Type (2017-2028)
Figure 31. Global Ultra Short Acting Benzodiazepines Revenue Market Share by Type (2017-2028)
Figure 32. Global Ultra Short Acting Benzodiazepines Sales Market Share by Application (2017-2028)
Figure 33. Global Ultra Short Acting Benzodiazepines Revenue Market Share by Application (2017-2028)
Figure 34. North America Ultra Short Acting Benzodiazepines Sales Market Share by Type (2017-2028)
Figure 35. North America Ultra Short Acting Benzodiazepines Revenue Market Share by Type (2017-2028)
Figure 36. North America Ultra Short Acting Benzodiazepines Sales Market Share by Application (2017-2028)
Figure 37. North America Ultra Short Acting Benzodiazepines Revenue Market Share by Application (2017-2028)
Figure 38. North America Ultra Short Acting Benzodiazepines Sales Share by Country (2017-2028)
Figure 39. North America Ultra Short Acting Benzodiazepines Revenue Share by Country (2017-2028)
Figure 40. United States Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Ultra Short Acting Benzodiazepines Sales Market Share by Type (2017-2028)
Figure 43. Europe Ultra Short Acting Benzodiazepines Revenue Market Share by Type (2017-2028)
Figure 44. Europe Ultra Short Acting Benzodiazepines Sales Market Share by Application (2017-2028)
Figure 45. Europe Ultra Short Acting Benzodiazepines Revenue Market Share by Application (2017-2028)
Figure 46. Europe Ultra Short Acting Benzodiazepines Sales Share by Country (2017-2028)
Figure 47. Europe Ultra Short Acting Benzodiazepines Revenue Share by Country (2017-2028)
Figure 48. Germany Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 49. France Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Ultra Short Acting Benzodiazepines Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Ultra Short Acting Benzodiazepines Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Ultra Short Acting Benzodiazepines Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Ultra Short Acting Benzodiazepines Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Ultra Short Acting Benzodiazepines Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Ultra Short Acting Benzodiazepines Revenue Share by Region (2017-2028)
Figure 59. China Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 62. India Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Ultra Short Acting Benzodiazepines Sales Market Share by Type (2017-2028)
Figure 69. Latin America Ultra Short Acting Benzodiazepines Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Ultra Short Acting Benzodiazepines Sales Market Share by Application (2017-2028)
Figure 71. Latin America Ultra Short Acting Benzodiazepines Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Ultra Short Acting Benzodiazepines Sales Share by Country (2017-2028)
Figure 73. Latin America Ultra Short Acting Benzodiazepines Revenue Share by Country (2017-2028)
Figure 74. Mexico Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Ultra Short Acting Benzodiazepines Sales Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Ultra Short Acting Benzodiazepines Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Ultra Short Acting Benzodiazepines Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Ultra Short Acting Benzodiazepines Revenue Share by Country (2017-2028)
Figure 83. Turkey Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 85. UAE Ultra Short Acting Benzodiazepines Revenue (2017-2028) & (US$ Million)
Figure 86. Ultra Short Acting Benzodiazepines Value Chain
Figure 87. Ultra Short Acting Benzodiazepines Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed


★調査レポート[超短時間作用型ベンゾジアゼピンの世界市場インサイト・予測（～2028年）] (コード：QY22JLX10511)販売に関する免責事項を必ずご確認ください。
★調査レポート[超短時間作用型ベンゾジアゼピンの世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 超短時間作用型バルビツール酸塩の世界市場インサイト・予測（～2028年）
  • 超短時間作用型ベータ遮断薬の世界市場インサイト・予測（～2028年）
  • 超短時間作用型麻酔薬の世界市場インサイト・予測（～2028年）
  • 超短時間作用型インスリンの世界市場インサイト・予測（～2028年）
  • 超長時間作用型インスリンの世界市場インサイト・予測（～2028年）

    • ◆H&Iグローバルリサーチのお客様（例）◆